Safety Assessment For Acute Vasoreactivity Test Using Inhaled Nitric Oxide Delivery System In Pulmonary Hypertension

Minatsuki shun0 个研究点目标入组 40 人开始时间: 2023年2月16日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•[Primary Enroll]
•(1). Suspected of pulmonary hypertension (tricuspid regurgitation velocity >= 2.8 m/s) or diagnosed with pulmonary hypertension (mean pulmonary artery pressure >= 21 mmHg)
•(2). Scheduled to have a right heart catheterization to diagnose or evaluate pulmonary hypertension
•(3). Aged 18 years and above at the time of informed consent is taken
•(4). Male or female
•(5). Able and willing to give written informed consent with sufficient understanding after having received sufficient explanation
•[Secondary Enroll]
•(1). Mean pulmonary artery pressure >= 21 mmHg measured by right heart catheterization

•[Primary Enroll]
•(1). With pulmonary hypertension with a WHO functional class IV
•(2). Systolic blood pressure <= 90 mmHg
•(3). Resting room air SpO2 <= 90%
•(4). Unable to give written informed consent (e.g. impaired consciousness, mental disorder)
•(5). Judged as ineligible by clinical investigators
•[Secondary Enroll]
•(1). Systolic blood pressure <= 90 mmHg during the right heart catheterization
•(2). Resting room air SpO2 <= 90% during the right heart catheterization
•(3). Judged as ineligible by clinical investigators according to the state or the result of the right heart catheterization

发起方

Minatsuki shun